Serological immunoreactivity against colon cancer proteome varies upon disease progression

J Proteome Res. 2008 Feb;7(2):504-14. doi: 10.1021/pr070360m. Epub 2008 Jan 8.

Abstract

Sera from colon carcinoma patients were used to identify tumor-associated antigens (TAAs) by screening tumor proteome resolved by 2D electrophoresis. A panel of six TAAs eliciting a serological immune response in colorectal cancer was identified, showing a modification in antigen recognition by B cells in patients as a function of colon cancer progression. The expression of these proteins was either confined or increased in tumor as compared to normal mucosa.

Publication types

  • Comparative Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adenocarcinoma / immunology
  • Adenocarcinoma / metabolism
  • Adenocarcinoma / pathology
  • Adult
  • Aged
  • Aged, 80 and over
  • Antibodies, Neoplasm / biosynthesis
  • Antibodies, Neoplasm / genetics
  • Antibodies, Neoplasm / metabolism
  • Antigens, Neoplasm / immunology*
  • Antigens, Neoplasm / metabolism
  • Cell Line, Tumor
  • Colonic Neoplasms / immunology*
  • Colonic Neoplasms / metabolism*
  • Colonic Neoplasms / pathology
  • Disease Progression
  • Electrophoresis, Gel, Two-Dimensional
  • Female
  • HT29 Cells
  • Humans
  • Male
  • Middle Aged
  • Proteome / immunology*
  • Proteome / metabolism
  • Proteomics

Substances

  • Antibodies, Neoplasm
  • Antigens, Neoplasm
  • Proteome